Loading…

HbA 1c screening for new onset diabetes following acute coronary syndrome: is it a worthwhile test in clinical practice?

Diabetes and pre-diabetes are prevalent in acute coronary syndrome (ACS) and relate to adverse outcomes. This study used HbA to screen for degrees of glucose intolerance amongst patients without known diabetes presenting with ACS. Over a 1-year period (June 2014-2015) consecutive patients admitted t...

Full description

Saved in:
Bibliographic Details
Published in:Journal of diabetes and metabolic disorders 2017, Vol.16, p.14
Main Authors: Lugg, Sebastian T, May, Christine J H, Nightingale, Peter, Tuffley, Robbie P E, Al-Hourani, June, De, Parijat
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites
container_end_page
container_issue
container_start_page 14
container_title Journal of diabetes and metabolic disorders
container_volume 16
creator Lugg, Sebastian T
May, Christine J H
Nightingale, Peter
Tuffley, Robbie P E
Al-Hourani, June
De, Parijat
description Diabetes and pre-diabetes are prevalent in acute coronary syndrome (ACS) and relate to adverse outcomes. This study used HbA to screen for degrees of glucose intolerance amongst patients without known diabetes presenting with ACS. Over a 1-year period (June 2014-2015) consecutive patients admitted to a single centre cardiology unit with an initial diagnosis of ACS without prior diabetes diagnosis were electronically referred to our diabetes team. Patients were screened for the presence of diabetes by use of an initial HbA blood test on day 2 or 3 post admission. If abnormal (≥42 mmol/mol; ≥6.0%), patients were invited for a repeat HbA at 2 weeks, and if an intermediate result (42-47 mmol/mol; 6.0-6.4%), for an oral glucose tolerance test (OGTT) at 3 months. Patients were diagnosed with Type 2 diabetes if the repeat HbA result was high (≥48 mmol/mol; ≥6.5%) or the OGTT at 3 months confirmed the diagnosis. Other data collected included baseline demographics, risk factors and any history of cardiovascular disease. All patients with ACS were stratified according to the diagnosis and subsequent management. We screened 399 patients in total. The mean age was 65 ± 14 years, 268 (67%) were men, 290 (73%) were Caucasian, 95 (24%) were South Asian and 14 (4%) were Afro-Caribbean ethnicity. Of all patients, 57 (14.3%) were diagnosed as pre-diabetes and 43 (10.8%) newly diagnosed diabetes. During the study 28 (7%) patients could not be classified; 6 (1.5%) patients died during the study and 22 (5.5%) patients were missing either initial or repeat HbA and were subsequently lost to follow up. Of the baseline variables assessed, there were significantly more patients of South Asian ethnicity in the diabetes group compared to the normal group (42 vs 20%;  = 0.003). There was no difference in detection rates in patients with more severe ACS requiring percutaneous or cardiac surgical intervention. The use of a simple HbA screening method in clinical practice can detect new onset diabetes in approximately 1 in 10 high-risk post ACS patients.
doi_str_mv 10.1186/s40200-017-0296-4
format article
fullrecord <record><control><sourceid>pubmed</sourceid><recordid>TN_cdi_pubmed_primary_28396850</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>28396850</sourcerecordid><originalsourceid>FETCH-pubmed_primary_283968503</originalsourceid><addsrcrecordid>eNqFTsFKAzEUDGJpi-0H9CLvB6JJ2s2mXkSK0g_wXrLZV_skmyxJytq_d4UK3pzLDMPMMIytpHiQ0ujHvBFKCC5kzYXaar65YXOlKsl1ZeTtHz1jy5w_xYi6NkbqKZsps95qU4k5-9o3LyAdZJcQA4UPOMYEAQeIIWOBlmyDBfNoex-Hn4B154LgYorBpgvkS2hT7PAJKAMVsDDEVE7DiTzC2CxAAZynQM566JN1hRw-L9jkaH3G5ZXv2P3b6_tuz_tz02F76BN14_zh9-r638A3B-lSrw</addsrcrecordid><sourcetype>Index Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>HbA 1c screening for new onset diabetes following acute coronary syndrome: is it a worthwhile test in clinical practice?</title><source>Springer Nature</source><source>PubMed Central</source><creator>Lugg, Sebastian T ; May, Christine J H ; Nightingale, Peter ; Tuffley, Robbie P E ; Al-Hourani, June ; De, Parijat</creator><creatorcontrib>Lugg, Sebastian T ; May, Christine J H ; Nightingale, Peter ; Tuffley, Robbie P E ; Al-Hourani, June ; De, Parijat</creatorcontrib><description>Diabetes and pre-diabetes are prevalent in acute coronary syndrome (ACS) and relate to adverse outcomes. This study used HbA to screen for degrees of glucose intolerance amongst patients without known diabetes presenting with ACS. Over a 1-year period (June 2014-2015) consecutive patients admitted to a single centre cardiology unit with an initial diagnosis of ACS without prior diabetes diagnosis were electronically referred to our diabetes team. Patients were screened for the presence of diabetes by use of an initial HbA blood test on day 2 or 3 post admission. If abnormal (≥42 mmol/mol; ≥6.0%), patients were invited for a repeat HbA at 2 weeks, and if an intermediate result (42-47 mmol/mol; 6.0-6.4%), for an oral glucose tolerance test (OGTT) at 3 months. Patients were diagnosed with Type 2 diabetes if the repeat HbA result was high (≥48 mmol/mol; ≥6.5%) or the OGTT at 3 months confirmed the diagnosis. Other data collected included baseline demographics, risk factors and any history of cardiovascular disease. All patients with ACS were stratified according to the diagnosis and subsequent management. We screened 399 patients in total. The mean age was 65 ± 14 years, 268 (67%) were men, 290 (73%) were Caucasian, 95 (24%) were South Asian and 14 (4%) were Afro-Caribbean ethnicity. Of all patients, 57 (14.3%) were diagnosed as pre-diabetes and 43 (10.8%) newly diagnosed diabetes. During the study 28 (7%) patients could not be classified; 6 (1.5%) patients died during the study and 22 (5.5%) patients were missing either initial or repeat HbA and were subsequently lost to follow up. Of the baseline variables assessed, there were significantly more patients of South Asian ethnicity in the diabetes group compared to the normal group (42 vs 20%;  = 0.003). There was no difference in detection rates in patients with more severe ACS requiring percutaneous or cardiac surgical intervention. The use of a simple HbA screening method in clinical practice can detect new onset diabetes in approximately 1 in 10 high-risk post ACS patients.</description><identifier>ISSN: 2251-6581</identifier><identifier>EISSN: 2251-6581</identifier><identifier>DOI: 10.1186/s40200-017-0296-4</identifier><identifier>PMID: 28396850</identifier><language>eng</language><publisher>Switzerland</publisher><ispartof>Journal of diabetes and metabolic disorders, 2017, Vol.16, p.14</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,4010,27900,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28396850$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Lugg, Sebastian T</creatorcontrib><creatorcontrib>May, Christine J H</creatorcontrib><creatorcontrib>Nightingale, Peter</creatorcontrib><creatorcontrib>Tuffley, Robbie P E</creatorcontrib><creatorcontrib>Al-Hourani, June</creatorcontrib><creatorcontrib>De, Parijat</creatorcontrib><title>HbA 1c screening for new onset diabetes following acute coronary syndrome: is it a worthwhile test in clinical practice?</title><title>Journal of diabetes and metabolic disorders</title><addtitle>J Diabetes Metab Disord</addtitle><description>Diabetes and pre-diabetes are prevalent in acute coronary syndrome (ACS) and relate to adverse outcomes. This study used HbA to screen for degrees of glucose intolerance amongst patients without known diabetes presenting with ACS. Over a 1-year period (June 2014-2015) consecutive patients admitted to a single centre cardiology unit with an initial diagnosis of ACS without prior diabetes diagnosis were electronically referred to our diabetes team. Patients were screened for the presence of diabetes by use of an initial HbA blood test on day 2 or 3 post admission. If abnormal (≥42 mmol/mol; ≥6.0%), patients were invited for a repeat HbA at 2 weeks, and if an intermediate result (42-47 mmol/mol; 6.0-6.4%), for an oral glucose tolerance test (OGTT) at 3 months. Patients were diagnosed with Type 2 diabetes if the repeat HbA result was high (≥48 mmol/mol; ≥6.5%) or the OGTT at 3 months confirmed the diagnosis. Other data collected included baseline demographics, risk factors and any history of cardiovascular disease. All patients with ACS were stratified according to the diagnosis and subsequent management. We screened 399 patients in total. The mean age was 65 ± 14 years, 268 (67%) were men, 290 (73%) were Caucasian, 95 (24%) were South Asian and 14 (4%) were Afro-Caribbean ethnicity. Of all patients, 57 (14.3%) were diagnosed as pre-diabetes and 43 (10.8%) newly diagnosed diabetes. During the study 28 (7%) patients could not be classified; 6 (1.5%) patients died during the study and 22 (5.5%) patients were missing either initial or repeat HbA and were subsequently lost to follow up. Of the baseline variables assessed, there were significantly more patients of South Asian ethnicity in the diabetes group compared to the normal group (42 vs 20%;  = 0.003). There was no difference in detection rates in patients with more severe ACS requiring percutaneous or cardiac surgical intervention. The use of a simple HbA screening method in clinical practice can detect new onset diabetes in approximately 1 in 10 high-risk post ACS patients.</description><issn>2251-6581</issn><issn>2251-6581</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><recordid>eNqFTsFKAzEUDGJpi-0H9CLvB6JJ2s2mXkSK0g_wXrLZV_skmyxJytq_d4UK3pzLDMPMMIytpHiQ0ujHvBFKCC5kzYXaar65YXOlKsl1ZeTtHz1jy5w_xYi6NkbqKZsps95qU4k5-9o3LyAdZJcQA4UPOMYEAQeIIWOBlmyDBfNoex-Hn4B154LgYorBpgvkS2hT7PAJKAMVsDDEVE7DiTzC2CxAAZynQM566JN1hRw-L9jkaH3G5ZXv2P3b6_tuz_tz02F76BN14_zh9-r638A3B-lSrw</recordid><startdate>2017</startdate><enddate>2017</enddate><creator>Lugg, Sebastian T</creator><creator>May, Christine J H</creator><creator>Nightingale, Peter</creator><creator>Tuffley, Robbie P E</creator><creator>Al-Hourani, June</creator><creator>De, Parijat</creator><scope>NPM</scope></search><sort><creationdate>2017</creationdate><title>HbA 1c screening for new onset diabetes following acute coronary syndrome: is it a worthwhile test in clinical practice?</title><author>Lugg, Sebastian T ; May, Christine J H ; Nightingale, Peter ; Tuffley, Robbie P E ; Al-Hourani, June ; De, Parijat</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-pubmed_primary_283968503</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Lugg, Sebastian T</creatorcontrib><creatorcontrib>May, Christine J H</creatorcontrib><creatorcontrib>Nightingale, Peter</creatorcontrib><creatorcontrib>Tuffley, Robbie P E</creatorcontrib><creatorcontrib>Al-Hourani, June</creatorcontrib><creatorcontrib>De, Parijat</creatorcontrib><collection>PubMed</collection><jtitle>Journal of diabetes and metabolic disorders</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Lugg, Sebastian T</au><au>May, Christine J H</au><au>Nightingale, Peter</au><au>Tuffley, Robbie P E</au><au>Al-Hourani, June</au><au>De, Parijat</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>HbA 1c screening for new onset diabetes following acute coronary syndrome: is it a worthwhile test in clinical practice?</atitle><jtitle>Journal of diabetes and metabolic disorders</jtitle><addtitle>J Diabetes Metab Disord</addtitle><date>2017</date><risdate>2017</risdate><volume>16</volume><spage>14</spage><pages>14-</pages><issn>2251-6581</issn><eissn>2251-6581</eissn><abstract>Diabetes and pre-diabetes are prevalent in acute coronary syndrome (ACS) and relate to adverse outcomes. This study used HbA to screen for degrees of glucose intolerance amongst patients without known diabetes presenting with ACS. Over a 1-year period (June 2014-2015) consecutive patients admitted to a single centre cardiology unit with an initial diagnosis of ACS without prior diabetes diagnosis were electronically referred to our diabetes team. Patients were screened for the presence of diabetes by use of an initial HbA blood test on day 2 or 3 post admission. If abnormal (≥42 mmol/mol; ≥6.0%), patients were invited for a repeat HbA at 2 weeks, and if an intermediate result (42-47 mmol/mol; 6.0-6.4%), for an oral glucose tolerance test (OGTT) at 3 months. Patients were diagnosed with Type 2 diabetes if the repeat HbA result was high (≥48 mmol/mol; ≥6.5%) or the OGTT at 3 months confirmed the diagnosis. Other data collected included baseline demographics, risk factors and any history of cardiovascular disease. All patients with ACS were stratified according to the diagnosis and subsequent management. We screened 399 patients in total. The mean age was 65 ± 14 years, 268 (67%) were men, 290 (73%) were Caucasian, 95 (24%) were South Asian and 14 (4%) were Afro-Caribbean ethnicity. Of all patients, 57 (14.3%) were diagnosed as pre-diabetes and 43 (10.8%) newly diagnosed diabetes. During the study 28 (7%) patients could not be classified; 6 (1.5%) patients died during the study and 22 (5.5%) patients were missing either initial or repeat HbA and were subsequently lost to follow up. Of the baseline variables assessed, there were significantly more patients of South Asian ethnicity in the diabetes group compared to the normal group (42 vs 20%;  = 0.003). There was no difference in detection rates in patients with more severe ACS requiring percutaneous or cardiac surgical intervention. The use of a simple HbA screening method in clinical practice can detect new onset diabetes in approximately 1 in 10 high-risk post ACS patients.</abstract><cop>Switzerland</cop><pmid>28396850</pmid><doi>10.1186/s40200-017-0296-4</doi></addata></record>
fulltext fulltext
identifier ISSN: 2251-6581
ispartof Journal of diabetes and metabolic disorders, 2017, Vol.16, p.14
issn 2251-6581
2251-6581
language eng
recordid cdi_pubmed_primary_28396850
source Springer Nature; PubMed Central
title HbA 1c screening for new onset diabetes following acute coronary syndrome: is it a worthwhile test in clinical practice?
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T09%3A50%3A01IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=HbA%201c%20screening%20for%20new%20onset%20diabetes%20following%20acute%20coronary%20syndrome:%20is%20it%20a%20worthwhile%20test%20in%20clinical%20practice?&rft.jtitle=Journal%20of%20diabetes%20and%20metabolic%20disorders&rft.au=Lugg,%20Sebastian%20T&rft.date=2017&rft.volume=16&rft.spage=14&rft.pages=14-&rft.issn=2251-6581&rft.eissn=2251-6581&rft_id=info:doi/10.1186/s40200-017-0296-4&rft_dat=%3Cpubmed%3E28396850%3C/pubmed%3E%3Cgrp_id%3Ecdi_FETCH-pubmed_primary_283968503%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/28396850&rfr_iscdi=true